clinical trial · NCT05918692
A Phase 1 Study of BMF-500 in Adults With Acute Leukemia
Acute Myeloid LeukemiaBMF-500
brief summary
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.
started
Jul 26, 2023
primary completion
Apr 1, 2026
completion
Apr 1, 2026
last updated
Feb 23, 2026
detailed description
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adult patients with acute myeloid leukemia (AML), who may or may not be on Antifungals.
official title
A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study of BMF-500, an Oral Covalent FLT3 Inhibitor, in Adults With Acute Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol